EFFECTS OF METFORMIN ON HORMONAL PROFILE AND SEMINAL FLUID ANALYSIS IN OBESE INFERTILE MALE
Main Article Content
Abstract
Background:Overweight and obese men have an up to 50% higher rate of sub-fertility when compared with normal weight men. Possible management options include weight reduction by dieting or surgery and medical treatment to correct specific endocrine abnormalities, but as yet none has been proven to be effective.
Objective:To verify the impact of decreasing body mass index by giving metformin on hormonal profile and seminal fluid analysis in obese infertile male.
Methods: Eighteen obese patients whose body mass index was 30-40 kg/m2 and with mean age of 29 years (range: 22-42 years) with idiopathic asthenozoospermia were enrolled in the study. Standard semen analysis according to WHO and hormones assay which include: follicular stimulating hormone, luteinizing hormone, prolactin, testosterone, and estradiole were performed at baseline and after 12 weeks of therapy. The enrolled patients were asked to take metformin 850 mg twice daily orally for 12 weeks.
Results:A significant decrease (p<0.001) in sperm count and sperm activity after 12 weeks of treatment with metformin. While there is no significant differences with respect to other spermiological parameters. A statistically significant decrease in the level of serum prolactin after 12 weeks of treatment with metformin whereas no significant differences with respect to the level of other hormones.
Conclusions:Although metformin has the capacity to decrease the level of prolactin, it decreases the number and activity of sperms. Further studies are recommended to investigate whether there is any association between infertility in human males and chronic metformin use
Keywords: Metformin, infertility, male, prolactin, overweight, obese.
Objective:To verify the impact of decreasing body mass index by giving metformin on hormonal profile and seminal fluid analysis in obese infertile male.
Methods: Eighteen obese patients whose body mass index was 30-40 kg/m2 and with mean age of 29 years (range: 22-42 years) with idiopathic asthenozoospermia were enrolled in the study. Standard semen analysis according to WHO and hormones assay which include: follicular stimulating hormone, luteinizing hormone, prolactin, testosterone, and estradiole were performed at baseline and after 12 weeks of therapy. The enrolled patients were asked to take metformin 850 mg twice daily orally for 12 weeks.
Results:A significant decrease (p<0.001) in sperm count and sperm activity after 12 weeks of treatment with metformin. While there is no significant differences with respect to other spermiological parameters. A statistically significant decrease in the level of serum prolactin after 12 weeks of treatment with metformin whereas no significant differences with respect to the level of other hormones.
Conclusions:Although metformin has the capacity to decrease the level of prolactin, it decreases the number and activity of sperms. Further studies are recommended to investigate whether there is any association between infertility in human males and chronic metformin use
Keywords: Metformin, infertility, male, prolactin, overweight, obese.
Article Details
How to Cite
[1]
2016. EFFECTS OF METFORMIN ON HORMONAL PROFILE AND SEMINAL FLUID ANALYSIS IN OBESE INFERTILE MALE. Iraqi Journal of Medical Sciences. 13, 3 (Apr. 2016).
Issue
Section
Articles
How to Cite
[1]
2016. EFFECTS OF METFORMIN ON HORMONAL PROFILE AND SEMINAL FLUID ANALYSIS IN OBESE INFERTILE MALE. Iraqi Journal of Medical Sciences. 13, 3 (Apr. 2016).